Stock Traders Purchase High Volume of Oncology Institute Call Options (NASDAQ:TOI)

The Oncology Institute, Inc. (NASDAQ:TOI) was the target of some unusual options trading activity on Wednesday. Stock traders bought 7,930 call options on the company. This represents an increase of approximately 435% compared to the typical volume of 1,482 call options.

Insider Activity

In other news, Director Growth I. L.P. M33 sold 6,018,168 shares of Oncology Institute stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $3.09, for a total value of $18,596,139.12. Following the sale, the director directly owned 7,932,389 shares in the company, valued at $24,511,082.01. This trade represents a 43.14% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 8.50% of the company’s stock.

Hedge Funds Weigh In On Oncology Institute

Institutional investors have recently modified their holdings of the business. XTX Topco Ltd boosted its position in shares of Oncology Institute by 49.5% in the 1st quarter. XTX Topco Ltd now owns 55,698 shares of the company’s stock worth $63,000 after buying an additional 18,448 shares in the last quarter. WealthShield Partners LLC acquired a new position in Oncology Institute during the 1st quarter worth $80,000. Citizens Financial Group Inc. RI acquired a new position in shares of Oncology Institute in the 1st quarter worth approximately $71,000. Josh Arnold Investment Consultant LLC purchased a new stake in shares of Oncology Institute in the first quarter valued at $2,267,000. Finally, Goldman Sachs Group Inc. purchased a new stake in shares of Oncology Institute during the 1st quarter worth about $131,000. 36.86% of the stock is owned by institutional investors and hedge funds.

Oncology Institute Stock Performance

Shares of NASDAQ:TOI traded down $0.33 during trading on Wednesday, hitting $3.45. The stock had a trading volume of 2,574,660 shares, compared to its average volume of 1,647,278. The stock has a market capitalization of $322.11 million, a price-to-earnings ratio of -5.41 and a beta of 0.07. The company has a quick ratio of 1.39, a current ratio of 1.68 and a debt-to-equity ratio of 14.58. The stock has a 50-day simple moving average of $3.78 and a two-hundred day simple moving average of $3.35. Oncology Institute has a 12-month low of $0.13 and a 12-month high of $4.88.

Oncology Institute (NASDAQ:TOI) last issued its quarterly earnings results on Thursday, November 13th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.02). The company had revenue of $136.56 million during the quarter, compared to analysts’ expectations of $122.63 million. Oncology Institute had a negative return on equity of 1,527.21% and a negative net margin of 13.21%. Oncology Institute has set its FY 2025 guidance at EPS.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on TOI. BTIG Research reaffirmed a “buy” rating and set a $7.00 target price on shares of Oncology Institute in a research note on Tuesday, October 21st. Noble Financial initiated coverage on Oncology Institute in a report on Wednesday, July 23rd. They issued an “outperform” rating and a $8.00 price target on the stock. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Oncology Institute in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Oncology Institute presently has an average rating of “Moderate Buy” and an average target price of $7.00.

About Oncology Institute

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.